ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 256 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q4 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,574,198 | +159.1% | 100,258 | +235.2% | 0.09% | +118.6% |
| Q2 2023 | $1,379,656 | +15.0% | 29,908 | 0.0% | 0.04% | +7.5% |
| Q1 2023 | $1,199,311 | -13.4% | 29,908 | 0.0% | 0.04% | -14.9% |
| Q4 2022 | $1,385,638 | +11.9% | 29,908 | 0.0% | 0.05% | +6.8% |
| Q3 2022 | $1,238,000 | -30.6% | 29,908 | 0.0% | 0.04% | -26.7% |
| Q2 2022 | $1,784,000 | -17.9% | 29,908 | 0.0% | 0.06% | -1.6% |
| Q1 2022 | $2,172,000 | -13.6% | 29,908 | 0.0% | 0.06% | -6.2% |
| Q4 2021 | $2,515,000 | -6.7% | 29,908 | 0.0% | 0.06% | -14.5% |
| Q3 2021 | $2,697,000 | -5.4% | 29,908 | 0.0% | 0.08% | -8.4% |
| Q2 2021 | $2,852,000 | -16.2% | 29,908 | 0.0% | 0.08% | -22.4% |
| Q1 2021 | $3,405,000 | -20.7% | 29,908 | -3.5% | 0.11% | -24.1% |
| Q4 2020 | $4,292,000 | +68.4% | 31,008 | 0.0% | 0.14% | +46.9% |
| Q3 2020 | $2,549,000 | +1.5% | 31,008 | -3.4% | 0.10% | -5.0% |
| Q2 2020 | $2,511,000 | +70.7% | 32,108 | -3.0% | 0.10% | +38.4% |
| Q1 2020 | $1,471,000 | +5.3% | 33,108 | +1.2% | 0.07% | +32.7% |
| Q4 2019 | $1,397,000 | -0.9% | 32,708 | -0.8% | 0.06% | -11.3% |
| Q3 2019 | $1,410,000 | -32.1% | 32,958 | +0.8% | 0.06% | -34.0% |
| Q2 2019 | $2,077,000 | -8.5% | 32,708 | 0.0% | 0.09% | -42.3% |
| Q1 2019 | $2,269,000 | +59.6% | 32,708 | 0.0% | 0.16% | +44.2% |
| Q4 2018 | $1,422,000 | -43.9% | 32,708 | -1.5% | 0.11% | -36.5% |
| Q3 2018 | $2,535,000 | -0.2% | 33,208 | 0.0% | 0.18% | -3.8% |
| Q2 2018 | $2,540,000 | +129.4% | 33,208 | +53.0% | 0.18% | +112.6% |
| Q1 2018 | $1,107,000 | +12.5% | 21,708 | +2.4% | 0.09% | +11.5% |
| Q4 2017 | $984,000 | -12.9% | 21,208 | 0.0% | 0.08% | -19.6% |
| Q3 2017 | $1,130,000 | -20.5% | 21,208 | 0.0% | 0.10% | -19.8% |
| Q2 2017 | $1,421,000 | +9.8% | 21,208 | 0.0% | 0.12% | +6.1% |
| Q1 2017 | $1,294,000 | – | 21,208 | – | 0.11% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| GREAT POINT PARTNERS LLC | 727,426 | $25,932,737 | 4.72% |
| RTW INVESTMENTS, LP | 5,405,089 | $192,691,423 | 4.07% |
| First Light Asset Management, LLC | 1,125,032 | $40,107,391 | 3.81% |
| CHI Advisors LLC | 215,000 | $7,664,750 | 3.04% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 250,052 | $8,914,354 | 3.00% |
| SPHERA FUNDS MANAGEMENT LTD. | 259,135 | $9,238,163 | 1.68% |
| Rock Springs Capital Management LP | 1,476,441 | $52,635,122 | 1.41% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 679,459 | $24,222,713 | 1.31% |
| Privium Fund Management B.V. | 115,241 | $4,108,341 | 1.22% |
| SECTOR GAMMA AS | 115,166 | $4,105,668 | 1.05% |